Aardvark Therapeutics, Inc. announced progress in its Phase 3 HERO trial for ARD-101, aimed at treating hyperphagia associated with Prader-Willi Syndrome, with data expected in early 2026. The company ...
Clinical Trials Arena on MSN
MAIA activates new site for THIO-101 phase II trial
The trial is studying ateganosine followed by cemiplimab in NSCLC patients resistant to checkpoint inhibitors and chemotherapy.
Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Approval filing with FDA FDA-cleared IND updates detail latest efficacy data and enriched ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results